Could a new drug beat the current standard for septic shock?
NCT ID NCT06746753
First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 1 time
Summary
This study tests whether a drug called Angiotensin II works better than the usual treatment (norepinephrine) for people with septic shock, a life-threatening condition where blood pressure drops dangerously. About 78 adults with septic shock will receive either Angiotensin II or standard care to see which helps restore blood pressure and improve survival. The goal is to find better ways to treat this serious illness and reduce its high death rate.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEPTIC SHOCK are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Atrium Health Wake Forest Baptist
Winston-Salem, North Carolina, 27157, United States
-
Massachusetts General Hospital-Harvard
Boston, Massachusetts, 02114, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood markers may foretell brain fog after sepsis
- Can tracking immune chaos in sepsis reveal new treatment targets?
- Blood clot score may predict organ damage in septic shock
- Could a key hormone be missing in septic shock?
- Could a simple mineral cut the need for powerful blood-pressure drugs in septic shock?
- Blood filter could shield vessels in septic shock